 |
Immune Globulin Subcutaneous (Human), 20% Liquid |
|---|---|
| Trade Name | Hizentra |
| Orphan Indication | Chronic inflammatory demyelinating polyneuropathy |
| USA Market Approval | USA |
| USA Designation Date | 2014-08-18 00:00:00 |
| Sponsor | CSL Behring;P. O. Box 61501, 1020 First Avenue;King of Prussia, Pennsylvania, 19406 |
